Celltrion Seeks Global Drug, Manufacturing Partnerships

South Korean biopharmaceutical firm Celltrion will pursue new global partnerships in novel drug development, contract manufacturing, and supply chain resilience at the CPHI 2026 exhibition in Milan. The company aims to expand its business beyond biosimilars, which currently form its core operations.

Celltrion Diversifies Beyond Biosimilars

Celltrion will participate in CPHI 2026 from October 6 to 8, an event expected to draw over 60,000 industry professionals from 2,400 companies across more than 170 countries. The company plans to use the three-day event for business discussions rather than solely showcasing existing products, reflecting a strategy to diversify its growth drivers.

South Korean

The biopharmaceutical market faces intensifying competition, prompting Celltrion to seek additional opportunities in drug development and manufacturing. This strategic shift aims to leverage its expertise and production infrastructure in new areas.

Targeting Novel Drug Pipelines

A primary focus for Celltrion involves identifying global companies with complementary capabilities in novel drug development. The firm is particularly interested in areas such as oncology, obesity, metabolic disorders, and autoimmune diseases.

These partnerships are intended to expand Celltrion's next-generation pipeline and accelerate the development of new therapies. The company has participated in CPHI with its own booth for five consecutive years since 2022, indicating a sustained commitment to global engagement.

Strengthening Supply Chains and CDMO

Supply chain resilience represents another major theme for Supply chain resilience represents another major theme for Celltrion at the exhibition. The company plans to strengthen relationships with current raw material suppliers and contract manufacturing partners. Simultaneously, Celltrion will seek new collaborators to diversify its supply base and enhance cost competitiveness. This approach addresses the growing demand for contract development and manufacturing organization (CDMO) services within the biopharmaceutical sector. Celltrion intends to capitalize on its experience in antibody-based biologic drug development and its manufacturing capacity to explore customized CDMO partnerships. Industry observers note an increasing trend of outsourcing across the biopharmaceutical sector, as drugmakers seek greater flexibility in development and manufacturing processes. Outlook for Diversified Growth If Celltrion secures significant partnerships at CPHI 2026, the company could accelerate its diversification into novel drug markets, potentially reducing its reliance on biosimilars. This would likely lead to increased revenue streams and a more robust product portfolio, impacting its valuation and market position.

Conversely, if the exhibition yields limited new collaborations, Celltrion may face continued pressure from biosimilar market competition, potentially slowing its growth trajectory. The wider biopharmaceutical industry could see increased consolidation or specialized partnerships as companies adapt to evolving market dynamics and demand for outsourced services.